Technegas® was introduced to the medical community in 1986
Technegas® revenues are generated in over 64 countries via a combination of direct and distributor sales models
Over 4.7 million patient procedures have been delivered to date
Grow Technegas Sales 2022 sales revenue was $22.88 million – an increase of 32%
Expand the Use of Technegas There are currently 6 Cyclopharm sponsored Beyond PE clinical trials
Leverage core strengths to continue to accelerate our third-party distribution business
Identify, develop and commercialise complementary innovative technology
Whether you are a shareholder or not, you can subscribe to receive all company announcements through our email alerts service.
To join email alerts, simply fill in your details using the form below and nominate which announcements you would like to receive.
Your privacy is important to us. If you no longer want to receive email alerts, use the unsubscribe link. If you are a shareholder and want to change your details or check your holdings, then use the share registry information on the contact us page.